Slide 1: Second Quarter 2022 Earnings Presentation
ANGIODYNAMICS Second Quarter 2022 Earnings PresentationJanuary 6, 2022 1
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Corporate Developments – Q2 and YTD Highlights
Corporate Developments – Q2 and YTD Highlights 3 Continued focused investment in our 3 key Med Tech platforms: Auryon, Thrombectomy & NanoKnife Revised FY2021 Guidance 3 Updated FY22 Guidance $0.00 - $0.05 ~55% Commenced LMR of the AlphaVac Mechanical Thrombectomy device in SeptemberFull Market Laun
Slide 4: Q2 and YTD Highlights: Financial Performance
Second Quarter and YTD Highlights Q2 FY2022 Q2 FY2021 Change YTD FY2022 YTD FY2021 Change Revenue $78,280 $72,770 7.6% $155,251 $142,986 8.6% Gross Margin 51.8% 55.2% (340 bps) 52.0% 53.1% (110 bps) Net Loss ($8,351) ($4,268) ($4,083) ($15,323) ($8,536) ($6,787) GAAP EPS ($0.21) ($0.11) ($0.10) ($0.
Slide 5: Q2 and YTD Highlights: Med Tech and Med Device Revenue
Second Quarter and YTD Highlights 5 Med Device Med Tech $10.5 $17.6 $59.7 $59.4 36.4% growth 0.8% growth Q2 Revenue Growth Q2 FY21 Q2 FY22 YTD Revenue Contribution Med Device Med Tech YTD FY21 YTD FY22 50.0% growth 0.1% growth Q2 Revenue Contribution YTD Revenue Growth
Slide 6: Highlights – Sales Growth Over Prior Periods
Second Quarter Highlights – Sales Growth Over Prior Periods Endovascular Therapies Q2 FY2022 YTD FY2022 Auryon 201% 285% Mechanical Thrombectomy* 29% 21% Thrombolytics (12%) (10%) Core Peripheral 5% 9% Venous Insufficiency (9%) (1%) Vascular Access Q2 FY2022 YTD FY2022 Midlines (5%) (25%) C3 (2%) 27
Slide 7: Q2 and YTD FY2022 Results (unaudited)
Second Quarter and YTD FY2022 Results (unaudited) $ in thousands (except per share data) Q2 FY2022 Q2 FY2021 Change YTD FY2022 YTD FY2021 Change Revenue $78,280 $72,770 7.6% $155,251 $142,986 8.6% Med Tech Med Device $18,886$59,394 $13,849$58,921 36.4%0.8% $36,504$118,747 $24,335$118,651 50.0%0.1% E
Slide 8: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 8
Slide 9: Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. Adjustment to re